Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials.
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study.
The
PLAATO implant consists of a spherical nitinol self-expanding metal cage with multiple struts that support an occlusive membrane of expanded polytetrafluoroethylene (an echo-reflective material due to microscopic trapped air), which occludes the lumen of the LAA and promotes healing.
The
PLAATO system was a device that was placed in the LAA via a transseptal catheter.
The
PLAATO device is a catheter-delivered, self-expanding nitinol cage covered with polytetrafluoroethylene anchored by hooks that stabilize the occluder in the left atrial appendage (LAA).
Lesh is now CEO of the company developing
PLAATO, Appriva Medical Inc., Sunnyvale, Calif.